TrivarX Completes Recruitment for 60-Patient Veterans Mental Health Trial Using Novel ECG Algorithm
核心洞察
TrivarX (搜索) has completed patient recruitment for its 60-patient clinical trial evaluating a single-lead ECG algorithm to screen for major depressive episodes (搜索) in veterans with suspected sleep apnea (搜索).
The trial, conducted in collaboration with the Greater Los Angeles Research and Education Foundation (搜索) and US Veterans Affairs Greater Los Angeles Healthcare System (搜索), follows promising interim results from 27 of the first 30 patients.
The single-channel ECG algorithm represents a potentially scalable, non-invasive tool for mental health assessment that could integrate with consumer devices like smartwatches.
TrivarX (搜索) Limited has completed patient recruitment for its clinical trial evaluating a novel single-lead ECG algorithm designed to screen for current major depressive episodes (搜索) in US veterans with suspected sleep apnea (搜索). The 60-patient trial represents a significant milestone for the Australian mental health technology company in developing objective measures for early detection of mental health conditions (搜索).
Trial Design and Collaboration
The clinical trial is being conducted in collaboration with the Greater Los Angeles Research and Education Foundation (搜索) (GLAVREF) and the US Veterans Affairs Greater Los Angeles Healthcare System (搜索). The study focuses specifically on veterans, a population with notably high rates of mental health issues, demonstrating the potential real-world impact of TrivarX (搜索)'s technology.
The trial utilizes TrivarX (搜索)'s single-channel algorithm based on heart rate (搜索) and heart rate variability (搜索) measurements. This approach represents an extension of the company's existing technology platform and offers the potential for integration with consumer devices such as smartwatches, creating a scalable screening solution.
Promising Interim Results Drive Completion
The completion of patient recruitment follows promising interim results from 27 of the first 30 patients enrolled in the study. These early positive indicators have supported the company's decision to complete the full recruitment target and maintain its development timeline.
TrivarX (搜索) expects to finalize the complete trial results later this quarter. These results will form the foundation for several key strategic initiatives, including engagement with regulatory agencies and discussions with commercial partners to explore potential applications and integrations of the technology.
Technology Platform and Applications
The single-lead ECG algorithm represents a potentially transformative approach to mental health screening by providing an objective, non-invasive assessment tool. Unlike traditional mental health screening methods that rely on subjective questionnaires and clinical interviews, TrivarX (搜索)'s technology uses physiological markers derived from heart rate (搜索) patterns to identify current major depressive episodes (搜索).
The technology's potential integration with consumer wearable devices could significantly expand access to mental health screening, particularly in underserved populations such as veterans who may face barriers to traditional mental healthcare services.
Company Profile and Market Position
TrivarX (搜索) Limited operates as a mental health technology company focused on pioneering objective measures for early detection and screening of mental health conditions (搜索). Founded in Australia with offices in Perth and Minneapolis, the company is listed on the Australian Securities Exchange and trades on the OTCQB Venture Market.
The company has demonstrated strong market performance with a year-to-date price increase of 68.75% and maintains a current market capitalization of A$16.74 million. The completion of this veteran-focused trial recruitment represents a key validation milestone for the company's technology platform and commercial strategy.